Tumor-associated peptide–Major Histocompatibility Complex on dendritic cells (pMHC-DC)

Tumor-associated peptide–Major Histocompatibility Complex (pMHC) on dendritic cells represents the fundamental interface for initiating an adaptive anti-tumor immune response. Dendritic cells (DCs), acting as professional antigen-presenting cells, internalize tumor-associated antigens (TAAs) or neoantigens and process them into short peptides that are loaded onto MHC Class I or Class II molecules (Nature Reviews Cancer, 2012). These complexes are then displayed on the DC surface to be recognized by specific T-cell receptors (TCRs) on naive or memory T cells, providing the 'Signal 1' necessary for T-cell activation and expansion (Journal of Clinical Investigation, 2015). In therapeutic contexts, this complex is the primary target of dendritic cell vaccines, such as Sipuleucel-T, which are designed to prime the patient's immune system to recognize and destroy malignant cells (FDA, 2010). The efficacy of targeting these complexes depends heavily on the selection of highly immunogenic peptides and the presence of appropriate human leukocyte antigen (HLA) types in the patient population. Furthermore, modern immunotherapies like TCR-like antibodies and engineered TCR-T cells are increasingly being developed to specifically bind these pMHC targets to bypass natural immune limitations (Frontiers in Immunology, 2020).

Other names

Peptide-MHC complexTumor antigen-MHC complexTA-pMHCMHC-restricted tumor antigenAntigen-MHC complex on APCs

Dendritic cell-mediated activation of T-cells through the presentation of tumor-associated antigens on MHC molecules, providing the primary signal for T-cell receptor (TCR) recognition and subsequent immune response.